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The patient was a 78-year-old man. In August 2007, he underwent catheter ablation for atrial ﬁbrillation
after taking bepridil for 3 weeks. Soon after the ablation, he experienced frequent atrial extrasystoles and
began taking bepridil again on the day he left the hospital. Six days after discharge, he was readmitted to
our hospital with dyspnea and was diagnosed with acute heart failure. The patient had no recurrence of
atrial ﬁbrillation, so the administration of bepridil was stopped. His dyspnea was eased using standard
therapy for heart failure and he was discharged from our hospital. In March 2011, he had a recurrence
of atrial ﬁbrillation and was readmitted to our hospital. The administration of bepridil was initiated
to deﬁbrillate the atrial ﬁbrillation. Although bepridil stopped the atrial ﬁbrillation by the third day, he
presented with dyspnea and fever on the fourth day. A chest radiograph showed bilateral interstitial
patterns that radiated from the pulmonary hilum. He was treated for acute heart failure and bacterial
pneumonia, but this was ineffective. We suspected that the interstitial pneumonia was caused by
bepridil. Corticosteroid therapy dramatically improved his symptoms. This was a rare case of acute drug-
induced interstitial pneumonia caused by repeated exposure to bepridil.
& 2012 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Bepridil is reported to be effective for pharmacological deﬁbrilla-
tion of atrial ﬁbrillation that has persisted for 3 months or more and
for the maintenance of sinus rhythm after electrical deﬁbrillation
[1,2]. Like amiodarone, bepridil has been reported to cause drug-
induced interstitial pneumonia in some cases [3,4]. We experienced
a case of acute drug-induced interstitial pneumonia, with severe
symptoms caused by short-term re-exposure to bepridil that com-
plicated the diagnosis.2. Case report
A 78-year-old man visited our hospital complaining of palpita-
tions resulting from a recurrence of atrial tachycardia and atrial
ﬁbrillation in March 2011. In August 2007, he was hospitalized twice
for catheter ablation of atrial ﬁbrillation and acute heart failure at the
age of 74. Bepridil was prescribed for 3 weeks before catheter
ablation and for a week just after catheter ablation, for frequent
extrasystoles at that time. Four years later, atrial tachycardia andrt Rhythm Society. Published by E
: þ81 4 2996 5200.ﬁbrillation recurred, and he was admitted to our hospital for the
arrhythmias. He was treated with 100mg/day of bepridil. By the
third day, the atrial ﬁbrillation converted to sinus rhythm (Fig. 1).
On the fourth day, he complained of dyspnea with exertion and his
body temperature rose. Fine crackles were slightly audible in the
bilateral lower lung ﬁelds. Hematology revealed high concentrations
of white blood cells (WBC, 9700/mL), C-reactive protein (CRP,
10.7 mg/dL), and brain natriuretic peptide (BNP, 521 ng/dL). The
alveolar-arterial oxygen difference (AaDO2) increased to 97 Torr and
he was administered oxygen (partial pressure [PaO2] of 77 Torr
with 3 L/min of O2). Pulmonary function test results revealed a mild
restrictive pattern (vital capacity: 67.8% of predicted), and decreasing
diffusing capacity for carbon monoxide (DLCO: 67.5% of predicted).
Bilateral interstitial patterns radiating from the pulmonary hilum
were observed in chest radiography (Fig. 2A, B). Chest computed
tomography (CT) scans revealed pleural effusion, patchy subpleural
ground-glass opacities, consolidation, and diffuse linear opacity in
the bilateral lung ﬁelds (Fig. 2C, D). We suspected acute heart failure
because of the negative inotropic drugs he was taking and con-
comitant bacterial pneumonia and administered standard therapy
for heart failure and antibiotics. Despite such therapy, his symptoms
and radiographic ﬁndings deteriorated each day.
Upon examining his previous hospital records from 4 years
prior, we found that he was diagnosed with acute heart failure at
the second hospitalization 1 week after catheter ablation for atriallsevier B.V. All rights reserved.
Fig. 1. Twelve-lead ECGs during atrial ﬁbrillation and sinus rhythm. (A) Twelve-lead ECG on the ﬁrst day of the third hospitalization showed recurrence of atrial
ﬁbrillation. (B) Administration of bepridil converted persistent atrial ﬁbrillation to sinus rhythm by the third day after bepridil administration.
Fig. 2. Chest radiography and computed tomography. (A) Chest radiograph before bepridil administration on the third hospitalization showed cardiomegaly (cardiac to
thoracic width ratio: 57%) without pleural effusions and cephalization of pulmonary vessels. (B) Chest radiograph on the 12th day after bepridil administration showed
bilateral pleural effusions and an interstitial pattern dilated from the pulmonary hilum. (C, D) Chest CT scan on the 12th day after bepridil administration revealed pleural
effusion, patchy subpleural ground-glass opacities, consolidation, and diffuse linear opacity in the bilateral lung ﬁelds.
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improved by standard therapy for heart failure, and the cause of
the heart failure had been thought to be a complication of negative
inotropic drugs or the cardiac catheter ablation, but this had not
been clariﬁed at the time. We noticed that bepridil was adminis-
tered for 3 weeks before the ﬁrst hospitalization for catheter
ablation and bepridil (100 mg/day) was administered after the
catheter ablation for 7 days prior to the second hospitalization for
acute heart failure. From these details, we speculated that the
diagnosis of heart failure of unknown etiology at the second
hospitalization could have been due to bepridil-induced interstitialpneumonia and, therefore, was possibly relieved by the fortuitous
cessation of bepridil (clinical course, medication, and laboratory data
are summarized in Fig. 3).
The results of right ventricular catheterization were normal
(mean pulmonary artery wedge pressure, 8 mmHg; cardiac index,
3.98 mL/min/m2) and heart failure was ruled out. Results of blood
tests after the appearance of dyspnea with exertion revealed high
concentrations of surfactant protein A (SP-A, 206 ng/mL) and
surfactant protein D (SP-D, 268 ng/mL), but KL-6 (311 U/mL)
was still within the normal range. However, KL-6 level increased
to 1132 U/mL, and SP-A and SP-D levels gradually decreased in
Fig. 3. Clinical course. The ﬁrst administration of bepridil did not cause dyspnea and elevation of CRP levels. CRP elevation and dyspnea occurred after bepridil
administration on both the second and third hospitalizations. The third administration of bepridil caused the rapid onset of dyspnea and CRP elevation, and as a result of
the longer duration of administration, the interstitial pneumonia was worse than that at the second hospitalization. Although serum SP-D and SP-A levels increased in the
acute phase of the interstitial pneumonia, serum KL-6 levels increased in its late phase. These serum markers for interstitial lung disease gradually decreased after the start
of corticosteroid therapy. CRP, C reactive protein; mPSL, methylprednisolone; PSL, prednisolone; and PVI, pulmonary vein isolation. Normal values: KL-6, o500 U/mL;
SP-D,o110 ng/mL; SP-A, o43.8 ng/mL.
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ﬂuid (BALF) revealed inﬂammatory cells (3.5105/mL); increased
percentages of neutrophils (13%), lymphocytes (37%), and eosi-
nocytes (9%); decreased percentage of macrophages (41%); 59.9%
CD4þ lymphocytes; and 17.9% CD8þ lymphocytes. The CD4þ/
CD8þ ratio was 3.35. Although the increases in inﬂammatory
cells and mixed cellularity in the BALF ﬁndings indicated inter-
stitial lung disease, this information was insufﬁcient for making a
deﬁnitive diagnosis. The drug lymphocyte stimulation test (DLST)
for bepridil was negative (90%), and a previous study indicated
that DLST is not always positive in bepridil-induced interstitial
pneumonia [5].
Our eventual diagnosis of drug-induced interstitial pneumonia
caused by bepridil was based on chest radiographic ﬁndings,
chest CT, BALF, and clinical processes. We stopped bepridil
administration on the 14th day and began administration of
30 mg of oral prednisolone after intravenous steroid pulse ther-
apy (methylprednisolone, 1000 mg/day) for 3 days. The patient’s
symptoms and chest radiography ﬁndings improved gradually.
We gradually reduced the dose of prednisolone, and 39 days
after starting prednisolone therapy, his respiratory failure had
improved from Hugh-Jones class V to class I and he was dis-
charged. At the time of discharge, he was able to walk by himself.3. Discussion
Among anti-arrhythmic drugs, amiodarone is well known to
induce interstitial pneumonia [6]. In view of bepridil’s blocking actionon sodium, potassium, and calcium channels in cardiomyocytes, it is
expected to have similar effects to amiodarone. However, the
induction of interstitial pneumonia may be a rare secondary effect
of bepridil, although some cases have been reported recently [3,4].
Our patient experienced respiratory symptoms and fever on the
fourth day when bepridil was administered for the third time. The
onset of bepridil-induced interstitial pneumonia was earlier in our
case than in previously reported cases, in which patients developed
bepridil-induced interstitial pneumonia at any time from 14 days
to 4200 days after administration of bepridil [3]. In the present
case, we noted that the underlying mechanism of bepridil-induced
interstitial pneumonia may have involved an immunoallergic reac-
tion rather than pulmonary toxicity resulting from drug accumula-
tion, as is sometimes the case with amiodarone. In the current case,
the longest period of administration of bepridil was only 3 weeks
before the ﬁrst hospitalization. If the interstitial pneumonia had
been induced by the direct pulmonary toxicity of bepridil, it would
have occurred more than 3 weeks after beginning administration.
At the time of the third hospitalization, the respiratory symptoms
occurred after only 4 days of bepridil administration, which is too
rapid to be caused by pulmonary toxicity.
The fact that interstitial pneumonia was induced at a low dose of
bepridil (100 mg/day) supports an immunoallergic mechanism
rather than a pulmonary toxicity mechanism. In the present case,
the dose of bepridil was lower than those in previously reported
cases (150–400 mg/day) [3] and it was given for a shorter period.
An immunoallergic mechanism would cause a small dose of bepridil
to induce interstitial pneumonia. Drug-speciﬁc antibodies tend to
be produced in cases of high-dose, long-term, recurrent exposure.
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immune allergic reaction and caused rapid onset of interstitial
pneumonia on the third hospitalization.
After initiating bepridil, interstitial pneumonia should be
considered a secondary effect of the drug so that it is discovered
early. In the repetitive, small-dose administration of bepridil, for
example as a temporary medication for terminating atrial ﬁbrilla-
tion, particular attention should be paid to respiratory symptoms
and fever. If such symptoms appear, bepridil should be immedi-
ately discontinued and the patient should be examined for
interstitial pneumonia through the measurement of parameters
such as SP-A, SP-D, and KL-6; chest radiographs; and CT. In this
case, SP-A and SP-D could be more useful for the early diagnosis
of bepridil-induced interstitial pneumonia than KL-6. However,
DLST may not be very useful in the diagnosis of drug-induced
interstitial pneumonia as it could yield negative results as shown
in some previous studies [6]. In addition, we could not perform a
lung biopsy because the patient was taking warfarin for atrial
ﬁbrillation. The BALF results suggested the presence of drug-
related lung injury, ruling out other problems such as common
bacterial infection and congestion of the lungs in heart
failure. The increase in levels of lymphocytes, neutrophils, and
eosinophils in BALF also supported the diagnosis of interstitial
lung disease.
In diagnosing drug-induced pneumonia, provocation testing
using the suspected drug is the most reliable method for assessing
the relationship between the particular drug and pneumonia
[7,8]. At the second hospitalization, the patient was diagnosed
with acute heart failure, and bepridil-induced interstitial
pneumonia had not been suspected. Most reported cases of
drug-induced lung diseases exhibit areas of consolidation, inﬁltrates,
or interstitial lesions on radiography and CT that are entirely
nonspeciﬁc and easily confused with the pulmonary abnormal-
ities caused by congestive heart failure, pneumonia, and pulmon-
ary infarction [9]. Because patients receiving anti-arrhythmic
agents have underlying cardiac disease, discriminating between
dyspnea caused by heart failure with negative inotropism and
drug-induced pulmonary disease is sometimes very difﬁcult.
This was a rare case of drug-induced interstitial pneumonia as
an adverse effect of bepridil. The patient had been treated for
acute heart failure at the second hospitalization when it was
fortunately discontinued on admission day because no atrial
extrasystoles were observed. The interstitial pneumonia was
relieved in 1 month despite receiving only standard treatment
for heart failure. When we diagnosed the patient with bepridil-
induced interstitial pneumonia at the third hospitalization, chest
radiographs and pulmonary CT scans were quite similar to those
at the second hospitalization. If we had noticed drug-inducedinterstitial pneumonia early at the third hospitalization, it might
have been resolved by stopping bepridil alone, with no need for
corticosteroid therapy. We should have observed drug-induced
interstitial pneumonia earlier and considered bepridil cessation.
Special attention should therefore be paid to drug-induced inter-
stitial pneumonia, even in the case of the repeated use of bepridil
for brief periods.4. Conclusions
We experienced a rare case in which the repeated short-term
administration of a low dose of bepridil (100 mg/day) induced
interstitial pneumonia. In medical practice, therapy with anti-
arrhythmic drugs is occasionally initiated or discontinued on the
basis of a patient’s arrhythmic events. Short-term and low-dose
administration of bepridil is possibly safer for patients than long-
term and high-dose administration. However, we have to remem-
ber that repeated short-term, low-dose administration of bepridil
can cause rapid occurrence of interstitial pneumonia as a result of
allergic reaction, and this should be considered in daily medical
practice.5. Conﬂict of interest
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